mavrostobart + pembrolizumab + carboplatin + pemetrexed

This is a multi-agent combination regimen consisting of **mavrostobart**, **pembrolizumab**, **carboplatin**, and **pemetrexed**. Pembrolizumab is a monoclonal antibody and immune checkpoint inhibitor targeting PD-1. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis. Pemetrexed is a multi-targeted antifolate chemotherapy that inhibits several enzymes necessary for DNA synthesis and cell replication. The combination of pembrolizumab, carboplatin, and pemetrexed is standard for the first-line treatment of metastatic nonsquamous non-small-cell lung cancer (NSCLC) and shows improved overall survival and progression-free survival compared to chemotherapy alone[1][2][3][4][5]. No clinical information is available for mavrostobart, indicating it may be an experimental or code name, unapproved or not widely recognized.